Volixibat potassium is a Small Molecule owned by Mirum Pharmaceuticals, and is involved in 10 clinical trials, of which 7 were completed, and 3 are ongoing.
Volixibat potassium (SHP-626, LUM-002) is a selective inhibitor of apical sodium-dependent bile acid transporter (ASBT). Increased intestinal bile acid absorption and expansion of the bile acid pool is implicated in hypercholesterolemia. The ileal apical sodium-dependent bile acid transporter is primarily responsible for active reabsorption of the majority of bile acids.
The revenue for Volixibat potassium is expected to reach a total of $362m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Volixibat potassium NPV Report.
Volixibat potassium Overview
Volixibat potassium (SHP-626, LUM-002) is under development for primary sclerosing cholangitis and its associated pruritus and primary biliary cholangitis. It is administered through the oral route as a capsule. The drug candidate selectively targets apical sodium-dependent bile acid transporter (ASBT). The human apical sodium-dependent bile acid transporter (SLC10A2) belongs to the solute carrier family (SLC) of transporters and is an important carrier protein expressed in the small intestine.
It was also under development for the treatment of nonalcoholic steatohepatitis (NASH) by Shire, adult cholestasis (intrahepatic cholestasis of pregnancy), and Type 2 diabetes.
Mirum Pharmaceuticals Overview
Mirum Pharmaceuticals is biopharmaceutical company that develops a pipeline of novel therapies for debilitating liver diseases. The company’s pipeline products include Maralixabat, minimally absorbed, orally administered investigational drug and Volixibat, a minimally absorbed agent designed to selectively inhibit ASBT. It develops products to treat rare cholestatic liver diseases that include progressive familial intrahepatic cholestasis (PFIC), alagille syndrome (ALGS), biliary atresia (BA), primary sclerosing cholangitis (PSC) and intrahepatic cholestasis of pregnancy (ICP). Mirum Pharmaceuticals is headquartered in Foster City, California, the US.
The company reported revenues of (US Dollars) US$19.1 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was US$65.4 million in FY2021, compared to an operating loss of US$104.3 million in FY2020. The net loss of the company was US$84 million in FY2021, compared to a net loss of US$103.3 million in FY2020. The company reported revenues of US$18.8 million for the third quarter ended September 2022, an increase of 7.4% over the previous quarter.
Quick View – Volixibat potassium
|Highest Development Stage|